FRANCISCO CARLOS DA COSTA DARRIEUX
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Coexistence of Wolff-Parkinson-White and Brugada Syndrome: Mere Curiosity?(2014) KAISER, Elisabeth; SACILOTTO, Luciana; DARRIEUX, Francisco; SOSA, EduardoThe association between Brugada syndrome (BS) and ventricular preexcitation is a rare condition, with sporadic cases already reported. We report the case of a 29-year-old man, with palpitation unrelated to physical or emotional stress. The electrocardiogram of the first visit revealed a ventricular preexcitation pattern and an end-conduction delay, with negative T wave in V-1 and intraventricular conduction disturbance in V-2 (atypical for BS). The typical aspect of BS occurred after introduction of propafenone for the prevention of atrioventricular tachycardia. We discuss the recognition of this rare association, the proarrhythmic effects of some drugs, treatment options, and prognosis.
- Baroreflex Sensitivity and its Association with Arrhythmic Events in Chagas Disease(2014) SANTOS, Astrid Meireles; SCANAVACCA, Mauricio Ibrahim; DARRIEUX, Francisco; IANNI, Barbara; MELO, Sissy Lara de; PISANI, Cristiano; NETO, Francisco Santos; SOSA, Eduardo; HACHUL, Denise TessariolBackground: Sudden death is the leading cause of death in Chagas disease (CD), even in patients with preserved ejection fraction (EF), suggesting that destabilizing factors of the arrhythmogenic substrate (autonomic modulation) contribute to its occurrence. Objective: To determine baroreflex sensitivity (BRS) in patients with undetermined CD (GI), arrhythmogenic CD with nonsustained ventricular tachycardia (NSVT) (GII) and CD with spontaneous sustained ventricular tachycardia (STV) (GIII), to evaluate its association with the occurrence and complexity of arrhythmias. Method: Forty-two patients with CD underwent ECG and continuous and noninvasive BP monitoring (TASK force monitor). The following were determined: BRS (phenylephrine method); heart rate variability (HRV) on 24-h Holter; and EF (echocardiogram). Results: GIII had lower BRS (6.09 ms/mm Hg) as compared to GII (11.84) and GI (15.23). The difference was significant between GI and GIII (p = 0.01). Correlating BRS with the density of ventricular extrasystoles (VE), low VE density (<10/h) was associated with preserved BRS. Only 59% of the patients with high VE density (>10/h) had preserved BRS (p = 0.003). Patients with depressed BRS had higher VE density (p = 0.01), regardless of the EF. The BRS was the only variable related to the occurrence of SVT (p = 0.028). Conclusion: The BRS is preserved in undetermined CD. The BRS impairment increases as disease progresses, being more severe in patients with more complex ventricular arrhythmias. The degree of autonomic dysfunction did not correlate with EF, but with the density and complexity of ventricular arrhythmias.
- Short-Coupled Variant of ""Torsades de Pointes"" and Polymorphic Ventricular Tachycardia(2014) CHOKR, Muhieddine Omar; DARRIEUX, Francisco Carlos da Costa; HARDY, Carina Abigail; HACHUL, Denise Tessariol; BRITTO, Allisson Valadao de Oliveira; MELO, Sissy Lara de; PISANI, Cristiano; SOSA, Eduardo Argentino; MARTINELLI FILHO, Martino; SCANAVACCA, Mauricio Ibrahim
- Late Outcome of a Randomized Study on Oral Magnesium for Premature Complexes(2014) FALCO, Cristina Nadja M. Lima De; DARRIEUX, Francisco Carlos da Costa; GRUPI, Cesar; SACILOTTO, Luciana; PISANI, Cristiano F.; LARA, Sissy; RAMIRES, Jose A. F.; SOSA, Eduardo; WU, Tan Chen; HACHUL, Denise; SCANAVACCA, MauricioBackground: Ventricular and supraventricular premature complexes (PC) are frequent and usually symptomatic. According to a previous study, magnesium pidolate (MgP) administration to symptomatic patients can improve the PC density and symptoms. Objective: To assess the late follow-up of that clinical intervention in patients treated with MgP or placebo. Methods: In the first phase of the study, 90 symptomatic and consecutive patients with PC were randomized (double-blind) to receive either MgP or placebo for 30 days. Monthly follow-up visits were conducted for 15 months to assess symptoms and control electrolytes. 24-hour Holter was performed twice, regardless of symptoms, or whenever symptoms were present. In the second phase of the study, relapsing patients, who had received MgP or placebo (crossing-over) in the first phase, were treated with MgP according to the same protocol. Results: Of the 45 patients initially treated with MgP, 17 (37.8%) relapsed during the 15-month follow-up, and the relapse time varied. Relapsing patients treated again had a statistically significant reduction in the PC density of 138.25/ hour (p < 0.001). The crossing-over patients reduced it by 247/ hour (p < 0.001). Patients who did not relapse, had a low PC frequency (3 PC/ hour). Retreated patients had a 76.5% improvement in symptom, and crossing-over patients, 71.4%. Conclusion: Some patients on MgP had relapse of symptoms and PC, indicating that MgP is neither a definitive nor a curative treatment for late follow-up. However, improvement in the PC frequency and symptoms was observed in the second phase of treatment, similar to the response in the first phase of treatment.